A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.
Exploring the efficacy and safety of fruquintinib combined with S-1 for second-line and beyond treatment in patients with advanced colorectal cancer.
Colorectal Cancer
DRUG: Fruquintinib+S-1
Progression free survival (PFS), Tumor assessment will be performed using radiography method every 6 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year
Objective response rate (ORR), Tumor assessment will be performed using radiography method every 6 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year|Overall survival (OS), Tumor assessment will be performed using radiography method every 6 weeks until the occurrence of progressive disease (PD)., from randomization until death due to any cause, assessed up to 3 year|Disease control rate (DCR), Tumor assessment will be performed using radiography method every 6 weeks until the occurrence of progressive disease (PD),using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year]|Safety and tolerance evaluated by incidence, severity and outcomes of AEs, Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 5.0, from first dose to 30 days post the last dose
Exploratory study endpoints., Circulating Tumor DNA (ctDNA) changes., Perform ctDNA tests on patients' blood at the start, after the first three cycles of treatment, and when disease progresses,from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year
Exploring the efficacy and safety of fruquintinib combined with S-1 for second-line and beyond treatment in patients with advanced colorectal cancer.